Next Article in Journal
Cell Line Models for Acquired Resistance to First-Line Osimertinib in Lung Cancers—Applications and Limitations
Previous Article in Journal
Dysregulation of PGC-1α-Dependent Transcriptional Programs in Neurological and Developmental Disorders: Therapeutic Challenges and Opportunities
 
 
Review

NF-κB in Cancer Immunity: Friend or Foe?

Cancer Research Center of Lyon, UMR INSERM 1052, CNRS 5286, Université Claude Bernard Lyon 1, Centre Léon Bérard, 69008 Lyon, France
*
Author to whom correspondence should be addressed.
Academic Editor: Matthew S. Hayden
Cells 2021, 10(2), 355; https://doi.org/10.3390/cells10020355
Received: 12 January 2021 / Revised: 29 January 2021 / Accepted: 5 February 2021 / Published: 9 February 2021
(This article belongs to the Special Issue The NF-kB Pathway as Therapeutic Target)
The emergence of immunotherapies has definitely proven the tight relationship between malignant and immune cells, its impact on cancer outcome and its therapeutic potential. In this context, it is undoubtedly critical to decipher the transcriptional regulation of these complex interactions. Following early observations demonstrating the roles of NF-κB in cancer initiation and progression, a series of studies converge to establish NF-κB as a master regulator of immune responses to cancer. Importantly, NF-κB is a family of transcriptional activators and repressors that can act at different stages of cancer immunity. In this review, we provide an overview of the selective cell-intrinsic contributions of NF-κB to the distinct cell types that compose the tumor immune environment. We also propose a new view of NF-κB targeting drugs as a new class of immunotherapies for cancer. View Full-Text
Keywords: onco-immunology; immunotherapy; NF-kappaB onco-immunology; immunotherapy; NF-kappaB
Show Figures

Figure 1

MDPI and ACS Style

Lalle, G.; Twardowski, J.; Grinberg-Bleyer, Y. NF-κB in Cancer Immunity: Friend or Foe? Cells 2021, 10, 355. https://doi.org/10.3390/cells10020355

AMA Style

Lalle G, Twardowski J, Grinberg-Bleyer Y. NF-κB in Cancer Immunity: Friend or Foe? Cells. 2021; 10(2):355. https://doi.org/10.3390/cells10020355

Chicago/Turabian Style

Lalle, Guilhem, Julie Twardowski, and Yenkel Grinberg-Bleyer. 2021. "NF-κB in Cancer Immunity: Friend or Foe?" Cells 10, no. 2: 355. https://doi.org/10.3390/cells10020355

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop